CNS endothelial cell activation emerges as a driver of CAR T cell –associated neurotoxicity

Cancer Discovery

Volumn 7, Issue 12, 2017, Pages 1371-1373

  Mackall, Crystal L ^a,b,c   Miklos, David B ^a,c  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD19 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; INTERLEUKIN 6; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; AUTOPSY; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BLOOD CLOTTING DISORDER; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; ENDOTHELIUM CELL; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LEUKOCYTE ADHERENCE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROVOCATION; RISK FACTOR; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; TOXICITY AND INTOXICATION;

CENTRAL NERVOUS SYSTEM; ENDOTHELIAL CELLS; HUMANS; NEUROTOXICITY SYNDROMES; T-LYMPHOCYTES;

EID: 85037357141     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-1084     Document Type: Article

References (14)

1. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
2. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517–28.
3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.
4. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139.
5. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123–38.
6. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells. Sci Transl Med 2016;8:355ra116.
7. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
8. Sattva SN, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy–assessment and management of toxicities. Nat Rev Clin Oncol 2017 Sep 19. [Epub ahead of print].
9. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404–19.
10. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol 2015;7:a020412.
11. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature 2010;468: 557–61.
12. Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med 2016;8:358ra128.
13. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis–a systematic review. Crit Care 2012;16:R7.
14. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27:2179–90.